Anticancer Drug Delivery: An Update on Clinically Applied Nanotherapeutics

Area of Science:

• Oncology
• Nanomedicine
• Drug Delivery

Background:

• Conventional chemotherapy faces challenges including poor solubility, pharmacokinetics, severe side effects, and multidrug resistance.
• Nanocarriers emerged to overcome these limitations, improving drug delivery and initiating nanomedicine in oncology.
• Liposomes, such as liposomal doxorubicin, are established nanovectors, with other systems like antibody drug conjugates and polymer-based systems in advanced trials.

Purpose of the Study:

• To review the application of nanotherapeutics in oncology.
• To identify successful nanomedicine concepts in cancer treatment.
• To discuss barriers to clinical translation and future directions for nanodrugs.

Main Methods:

• Literature review of nanotherapeutics in oncology.
• Analysis of successful nanomedicine concepts and clinical trial data.
• Discussion of challenges and opportunities in nanodrug development.

Main Results:

• Nanocarriers have shown promise in preclinical studies for improving chemotherapy delivery.
• Despite advancements, a significant gap exists between nanodrug design and successful clinical translation.
• Various nanocarrier systems, including liposomes and antibody drug conjugates, are utilized in cancer therapy.

Conclusions:

• Nanomedicine holds great potential for improving cancer treatment outcomes.
• Addressing challenges in clinical translation is crucial for realizing the full potential of nanodrugs.
• Further research and development efforts are needed to bridge the gap between nanodrug design and patient application.